Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms. Fortunately, a number of promising treatments have shown incredible potential—and with that comes the possibility of significant sales.
Two smaller biotech companies are experiencing significant share price growth momentum thanks to their leading oncology medicines. Besides offering powerful treatment potential, these drugs may be able to help the firms grow toward stability beyond penny stock (or otherwise unstable) status and even to long-term profitability. In both cases, challenges remain, making these typical biotech investments in many ways—high-risk ventures that also have the possibility of generating outsized rewards for investors willing to take a chance on them.
